European Neuropsychopharmacology
Volume 20, Issue 7 , Pages 454-458 , July 2010

Cigarette smoking and progressive brain volume loss in schizophrenia

Received 22 October 2009 ,Revised 21 December 2009 ,Accepted 13 February 2010.

References 

  1. Almeida OP, Garrido GJ, Lautenschlager NT, Hulse GK, Jamrozik K, Flicker L. Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzhe`mer disease. Am. J. Geriatr. Psychiatry. 2008;16:92–98
  2. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry. 1992;49:615–623
  3. Brody AL, Mandelkern MA, Jarvik ME, Lee GS, Smith EC, Huang JC, et al. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol. Psychiatry. 2004;55:77–84
  4. Foll BL, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb. Exp. Pharmacol. 2009;192:335–367
  5. Gallinat J, Meisenzahl E, Jacobsen LK, Kalus P, Bierbrauer J, Kienast T, et al. Smoking and structural brain deficits: a volumetric MR investigation. Eur. J. NeuroSci. 2006;24:1744–1750
  6. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36:267–275
  7. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008;34:354–366
  8. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  9. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606–2610
  10. Leonard S, Mexal S, Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual. Diagn. 2007;3:43–59
  11. Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 2005;31:672–696
  12. Phelan M, Slade M, Thornicroft G, Dunn G, Holloway F, Wykes T, et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br. J. Psychiatry. 1995;167:589–595
  13. Poirier MF, Canceil O, Bayle F, Millet B, Bourdel MC, Moatti C, et al. Prevalence of smoking in psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26:529–537
  14. Schnack HG, Hulshoff Pol HE, Baare WF, Staal WG, Viergever MA, Kahn RS. Automated separation of gray and white matter from MR images of the human brain. Neuroimage. 2001;13:230–237
  15. Schnack HG, Hulshoff HE, Baare WF, Viergever MA, Kahn RS. Automatic segmentation of the ventricular system from MR images of the human brain. Neuroimage. 2001;14:95–104
  16. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging. 1998;17:87–97
  17. Smitten MHt, Smeets RMW, Brink Wvd. Composite Interntional Diagnostic Interview (CIDI). Basis versie 2.1. Lifetime. Amsterdam: Psychiatrisch Centrum AMC; 1998;
  18. Stephens SH, Logel J, Barton A, Franks A, Schultz J, Short M, et al. Association of the 5′-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr. Res. 2009;109:102–112
  19. Tregellas JR, Shatti S, Tanabe JL, Martin LF, Gibson L, Wylie K, et al. Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. Schizophr. Res. 2007;97:242–249
  20. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Brans R, Carati I, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry. 2008;63:106–113
  21. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32:2057–2066

☆ This paper was presented at Human Brain Mapping, June 2008, Melbourne, Australia.

PII: S0924-977X(10)00042-8

doi: 10.1016/j.euroneuro.2010.02.009

European Neuropsychopharmacology
Volume 20, Issue 7 , Pages 454-458 , July 2010

Article Tools

* Image Usage & Resolution